ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBPBiotechnology
+$0.44 today
- Market cap
- $563.78M
- Beta
- 1.42
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$3.22
Volume 2.70M
Average 0.50M
AVBP EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
ArriVent BioPharma, Inc. Common StockNASDAQ: AVBP
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$43.32M, compared with -$64.39M a year earlier. Trailing-twelve-month EBITDA was -$145.24M.
Context
- EBITDA increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 7 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -106.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$43.32M-21.9% QoQ
- Last fiscal yearDec 2025
- -$166.31M-106.6% YoY
- LTMMar 2026
- -$145.24M-14.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +32.7% | +100.0% | +67.3 pp |
| 1 year | -106.6% | +100.0% | +206.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (166.31M) USD
- Year-over-year change
- -106.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (166.31M) | -106.6% |
| FY2024 | 2024-12-31 | (80.49M) | -16.1% |
| FY2023 | 2023-12-31 | (69.33M) | — |
| FY2022 | 2022-12-31 | 0 | +100.0% |
| FY2021 | 2021-12-31 | (51.61M) | — |
EBITDA vs competitors
How AVBP compares with its peers on the latest reported figures
- AVBP's LTM Mar 2026 EBITDA of -$145.24M is the 9th highest of the 11 companies compared; the peer median is -$128.8M.
- Its year-over-year change of -14.0% is the 7th highest of 11, against a peer median of +5.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $1.05B | +28.1% | +53.4% | 43.0% | |
| LTM Mar 2026 | $44.91M | -17.8% | +34.6% | 19.8% | |
| LTM Jun 2025 | -$7.49M | +93.2% | — | 1.2% | |
| LTM Mar 2026 | -$38.09M | -800.9% | — | — | |
| LTM Jun 2026 | -$127.04M | +36.8% | — | 74.8% | |
| LTM Mar 2026 | -$130.56M | -36.2% | — | — | |
| LTM Mar 2026 | -$134.03M | -1.8% | — | — | |
| LTM Mar 2026 | -$135.46M | +55.2% | — | 60.1% | |
| LTM Mar 2026 | -$145.24M | -14.0% | — | — | |
| LTM Jun 2026 | -$168.8M | +13.6% | — | 37.5% | |
| LTM Sep 2026 | -$305.05M | -151.6% | — | — | |
| Peer median (excluding AVBP) | -$128.8M | +5.9% | +44.0% | 40.3% | |
Competitors are the stored peer set for AVBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 6.43M | 30.43M | 64.88M | 79M | 153.35M |
| Selling, General & Admin | 2.26M | 6.47M | 9.71M | 15.3M | 24.18M |
| Operating Expenses | 8.7M | 36.91M | 74.59M | 94.31M | 177.53M |
| Depreciation & Amortization | 0 | 36.91M | 0 | 0 | 0 |
| EBITDA | (51.61M) | 0 | (69.33M) | (80.49M) | (166.31M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (8.7M) | (36.91M) | (74.59M) | (94.31M) | (177.53M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 5.26M | 13.82M | 11.23M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (42.91M) | 0 | 5.26M | 13.82M | 11.23M |
| Income Before Tax | (51.61M) | (36.91M) | (69.33M) | (80.49M) | (166.31M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (51.61M) | (36.91M) | (69.33M) | (80.49M) | (166.31M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (40.44) | (1.10) | (2.17) | (2.56) | (4.32) |
| EPS (Diluted) | (40.44) | (1.10) | (2.17) | (2.56) | (4.32) |
| Weighted Avg Shares | 1.28M | 33.49M | 31.96M | 31.47M | 38.46M |
| Weighted Avg Shares (Diluted) | 1.28M | 33.49M | 31.96M | 31.47M | 38.46M |
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.